{"id":"f-e550251d2f-0ce8a571-2062-5d3d-bf61-26a689ee4625","title":"Sudeep Pharma Q2 Results: Revenue rises but profit down, margins narrow","description":"Sudeep Pharma reports Q2 revenue growth but lower profits after Dalal Street debut. Shares of Sudeep Pharma ended higher on Friday, December 19, by 1.46% at ₹684 on the NSE.","timestamp":1766155764,"category":"business","headline":"Sudeep Pharma Q2 Results: Revenue rises but profit down, margins narrow","modifiedHeadline":"Sudeep Pharma Profit Fell Despite Revenue Rise","subCategories":["scid_4d81caea"],"region":"IN","bundleMetaData":{"bundleId":"ece1ae3d-908e-48c7-9e53-a4aa910ee4db","bundleTitle":"Grow Your Money","cardData":null},"iabCategoryId":"53","fcSummary":"Sudeep Pharma's Q2 results reveal a mixed performance, with a 9.3% revenue increase to ₹162.7 crore offset by a 6.15% drop in net profit to ₹45.8 crore. EBITDA and margins also declined, shortly after the company's successful IPO listing in late November.","summary":"Sudeep Pharma's Q2 sees revenue rise post-debut, but profit dips, sparking investor concerns. Margins narrow despite NSE share uptick.","ctaUrl":"https://trends.glance.com/newz/Economy/IN/en/cnbc-tv18/f-e550251d2f-0ce8a571-2062-5d3d-bf61-26a689ee4625","sourceUrl":"https://www.cnbctv18.com/market/stocks/sudeep-pharma-share-price-q2-results-profit-falls-6-pc-yoy-revenue-up-9-pc-ws-l-19797212.htm","bannerImage":"https://g-mob.glance-cdn.com/public/fc/image/nWpJlxKbhWN0.webp","content":"

Vadodara-based Sudeep Pharma on Friday, December 19, reported a mixed performance for the second quarter, with revenue growth offset by a drop in profitability.

\n\n

\n
\n

The company’s net profit fell 6.15% year-on-year to ₹45.8 crore, compared with ₹48.8 crore in the same quarter last year.

\n
\n

EBITDA declined 11.2% to ₹55.5 crore from ₹63.5 crore a year earlier, while EBITDA margin narrowed to 34.1% from 42.7%, reflecting margin pressure during the quarter.

\n\n
\n

Revenue, however, rose 9.3% year-on-year to ₹162.7 crore, up from ₹148.8 crore in the corresponding period last year.

\n
\n

The results come shortly after Sudeep Pharma’s debut on Dalal Street. The company was listed on November 28, with shares opening at ₹733.95 on the BSE against an issue price of ₹593, while the stock debuted at ₹730 on the NSE.

\n\n
\n

Ahead of the listing, Sudeep Pharma’s shares were trading at a premium of about 20.4% in the unlisted market. Based on a grey market premium (GMP) of ₹121, the stock was expected to list around ₹714.

\n
\n

The company’s ₹895 crore initial public offering (IPO) was open for subscription between November 21-25 and saw strong investor demand. The issue was subscribed 93.72 times, attracting bids worth over ₹58,700 crore across nearly 29.86 lakh applications.

\n
\n

Shares of Sudeep Pharma ended higher on Friday, December 19, by 1.46% at ₹684 on the NSE.

\n\n
\n

Also Read: Suraj Estate acquires 2 parcels of land in Mumbai's Bandra for new projects

","readDurationInMinutes":"3","author":{"name":"CNBC TV18","logo":"https://glance-mob.glance-cdn.com/public/bubble/jpeg/ecc3d19b-fc52-4a39-881c-5b0936ae723b.jpeg"},"ism":false,"analyticsResponses":[{"measurementId":"383191425","type":"COMSCORE"}],"pointerSummary":["Sudeep Pharma's Q2 net profit declined 6.15% to ₹45.8 crore, EBITDA down 11.2%.","Revenue rose 9.3% to ₹162.7 crore, but EBITDA margin narrowed to 34.1%.","IPO subscribed 93.72 times; Shares ended up 1.46% at ₹684 on NSE on Friday."],"tags":["SudeepPharma","Q2Results","FinancialResults","DalalStreet","NSE","BSE","IPO","Vadodara","RevenueGrowth","ProfitDecline","EBITDA","MarginPressure","StockMarket","InitialPublicOffering"],"redirectionEnabled":false,"consent":true}

Sudeep Pharma Q2 Results: Revenue rises but profit down, margins narrow

SUMMARY